# Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

> **NCT00206713** · PHASE3 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 264 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Sargramostim (Leukine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00206713
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206713, "Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00206713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*